Long-Term Outcomes of Cytomegalovirus Reactivation in Patients with Moderate to Severe Ulcerative Colitis: A Multicenter Study
0
조회
0
다운로드
9
인용
0
참고문헌
키워드
초록
Background/Aims: Cytomegalovirus (CMV) reactivations are frequently observed in patients with active ulcerative colitis (UC), and ganciclovir therapy is effective in patients with steroid-refractory UC. This study aimed to determine the long-term outcomes of CMV reactivation and the long-term thera-peutic efficacy of ganciclovir treatment. Methods: This retro-spective multicenter study included a cohort of 72 patients with moderate-to-severe UC who were evaluated for CMV reactivation at the time of their initial UC flare. Colectomy, disease relapse, and the recurrence rate of CMV reactivation were investigated. Results: The mean duration of follow-up for the 72 patients was 43.16±19.78 months (range, 1 to 67 months). The cumulative colectomy (log-rank, p=0.025) and disease flare-up rates (log-rank, p=0.048) were significantly higher in the CMV-positive group. Of the 11 patients who were successfully treated with ganciclovir in the initial treat-ment, three patients (27.3%) experienced CMV reactivation, and six patients (54.5%) experienced poor outcomes, such as the need for colectomy or a steroid-dependent state. Conclusions: The patients who had CMV-reactivated UC showed poor outcomes at the long-term follow-up, and the long-term efficacy of ganciclovir therapy was marginal. Careful assess-ment is necessary for patients who exhibit evidence of CMV reactivation.
Abstract
Background/Aims: Cytomegalovirus (CMV) reactivations are frequently observed in patients with active ulcerative colitis (UC), and ganciclovir therapy is effective in patients with steroid-refractory UC. This study aimed to determine the long-term outcomes of CMV reactivation and the long-term thera-peutic efficacy of ganciclovir treatment. Methods: This retro-spective multicenter study included a cohort of 72 patients with moderate-to-severe UC who were evaluated for CMV reactivation at the time of their initial UC flare. Colectomy, disease relapse, and the recurrence rate of CMV reactivation were investigated. Results: The mean duration of follow-up for the 72 patients was 43.16±19.78 months (range, 1 to 67 months). The cumulative colectomy (log-rank, p=0.025) and disease flare-up rates (log-rank, p=0.048) were significantly higher in the CMV-positive group. Of the 11 patients who were successfully treated with ganciclovir in the initial treat-ment, three patients (27.3%) experienced CMV reactivation, and six patients (54.5%) experienced poor outcomes, such as the need for colectomy or a steroid-dependent state. Conclusions: The patients who had CMV-reactivated UC showed poor outcomes at the long-term follow-up, and the long-term efficacy of ganciclovir therapy was marginal. Careful assess-ment is necessary for patients who exhibit evidence of CMV reactivation.
참고문헌 (21)
- de Jong MD, "Summary of the II International Symposium on Cytomegalovirus", Antiviral Res, 39, pp.141~162 (1998)
- Goodgame RW, "Gastrointestinal cytomegalovirus disease", Ann Intern Med, 119, pp.924~935 (1993)
- Soderberg-Naucler C, "Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system", Crit Rev Immunol, 26, pp.231~264 (2006)
- Söderberg-Nauclér C, "Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines", J Clin Invest, 100, pp.3154~3163 (1997)
- Nguyen M, "Cytomegalovirus reactivation in ulcerative colitis patients", Ulcers, 2011, pp.pii:282507~ (2011)
- Domènech E, "Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy", Inflamm Bowel Dis, 14, pp.1373~1379 (2008)
- Wada Y, "Intractable ulcerative colitis caused by cytomegalovirus infection: a prospective study on prevalence, diagnosis, and treatment", Dis Colon Rectum, 46, pp.S59~S65 (2003)
- Criscuoli V, "Severe acute colitis associated with CMV: a prevalence study", Dig Liver Dis, 36, pp.818~820 (2004)
- Cottone M, "Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis", Am J Gastroenterol, 96, pp.773~775 (2001)
- Kim YS, "The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study", J Clin Gastroenterol, 46, pp.51~56 (2012)
- Al-Zafiri R, "Cytomegalovirus complicating inflammatory bowel disease: a 10-year experience in a community-based, university-affiliated hospital", Gastroenterol Hepatol (N Y), 8, pp.230~239 (2012)
- Kim O, "Consistency of the low seroprevalence of human herpesvirus 8 and the rarity of Kaposi’s sarcoma in South Korea", J Bacteriol Virol, 31, pp.275~279 (2001)
- Yi F, "The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China", Virol J, 10, pp.43~ (2013)
- Dimitroulia E, "Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease", Inflamm Bowel Dis, 12, pp.879~884 (2006)
- Inoue K, "Toxic megacolon associated with cytomegalovirus infection in a patient with steroidnaïve ulcerative colitis", Intern Med, 51, pp.2739~2743 (2012)
- Pfau P, "Cytomegalovirus colitis complicating ulcerative colitis in the steroid-naive patient", Am J Gastroenterol, 96, pp.895~899 (2001)
- Kim YS, "Cytomegalovirus infection in patients with new onset ulcerative colitis: a prospective study", Hepatogastroenterology, 59, pp.1098~1101 (2012)
- Hiroshi Nakase, "Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation", Intestinal research, 12(1), pp.5~11 (2014), 대한장연구학회
- Park SH, "Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis", Dig Dis Sci, 58, pp.3592~3599 (2013)
- Ayre K, "The role of CMV in steroid-resistant ulcerative colitis: a systematic review", J Crohns Colitis, 3, pp.141~148 (2009)
- Rahier JF, "European evidencebased Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease", J Crohns Colitis, 3, pp.47~91 (2009)